6L8.F · Pulse Biosciences, Inc

-

Please sign in to comment on 6L8.F

1 Comment

Admin

3 years, 7 months ago

Pulse Biosciences, Inc is currently in a long term downtrend where the price is trading 15.2% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Pulse Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 0.3% to $-14M since the same quarter in the previous year.

Finally, its free cash flow fell by 3.7% to $-10M since the same quarter in the previous year.

Based on the above factors, Pulse Biosciences, Inc gets an overall score of 2/5.

ISIN	US74587B1017
CurrencyCode	EUR
Exchange	F
Industry	Medical Instruments & Supplies
Sector	Healthcare

Beta	1.12
PE Ratio	None
Market Cap	300M
Dividend Yield	0.0%
Target Price	38

ABOUT

Pulse Biosciences, Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.

6L8.F · Pulse Biosciences, Inc

-

Pulse Biosciences, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Pulse Biosciences, Inc using a moving average strategy